OncoMatch/Clinical Trials/NCT05887609
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
Is NCT05887609 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Mirvetuximab Soravtansine-gynx and Olaparib for ovary cancer.
Treatment: Mirvetuximab Soravtansine-gynx · Olaparib — The Principal Investigator hypothesizes the combination of MIRV and Olaparib is an effective, and tolerable, maintenance therapy strategy in platinum sensitive recurrent ovarian cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Ovarian Cancer
Biomarker criteria
Required: FOLR1 high or medium expression (high or medium)
Allowed: BRCA1 any mutation
Allowed: BRCA2 any mutation
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: platinum-based chemotherapy — recurrent disease
Patients must have received at least one prior platinum-based chemotherapy regimen for platinum sensitive recurrent disease
Must have received: PARP inhibitor — treatment or maintenance
if BRCA mutation positive, must have received a prior PARP inhibitor as either treatment or maintenance therapy
Cannot have received: FRα-targeting agent (mirvetuximab soravtansine)
Patients who received prior treatment with MIRV or other FRα- targeting agents
Cannot have received: allogenic bone marrow transplant or double umbilical cord blood transplantation
Previous allogenic bone marrow transplant or double umbilical cord blood transplantation (dUCBT)
Lab requirements
Blood counts
ANC ≥ 1.5 x 10^9/L (1500/µL); platelets ≥ 100 x 10^9/L (100,000/µL); hemoglobin ≥ 10.0 g/dL with no blood transfusion in past 28 days
Kidney function
serum creatinine ≤ 1.5 x ULN; creatinine clearance ≥51 mL/min (Cockcroft-Gault or 24h urine)
Liver function
AST/ALT ≤ 2.5 x ULN unless liver metastases are present in which case ≤ 5x ULN; serum bilirubin ≤ 1.5 x ULN (Gilbert syndrome eligible if total bilirubin < 3.0 x ULN); serum albumin ≥ 2 g/dL
Patients must have adequate hematologic, liver, and kidney function as defined as: ANC ≥ 1.5 x 10^9/L (1500/µL); Platelet count ≥ 100 x 10^9/L (100,000 µL); Hemoglobin ≥ 10.0 g/dL with no blood transfusion in the past 28 days; Serum creatinine ≤ 1.5 x ULN; creatinine clearance ≥51 mL/min; AST/ALT ≤ 2.5 x ULN unless liver metastases are present in which case ≤ 5x ULN; serum bilirubin ≤ 1.5 x ULN (Gilbert syndrome eligible if total bilirubin < 3.0 x ULN); serum albumin ≥ 2 g/dL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Colorado Hospital · Aurora, Colorado
- Northwestern Memorial Hospital · Chicago, Illinois
- University of Pennsylvania Health System, Perelman Center for Advanced Medicine · Philadelphia, Pennsylvania
- UPMC Magee-Women's Hospital · Pittsburgh, Pennsylvania
- University of Wisconsin - Carbone Cancer Center - University Hospital · Madison, Wisconsin
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05887609 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior FRα-targeting agent, allogenic bone marrow transplant or double umbilical cord blood transplantation disqualifies patients from enrollment.
Does this trial require FOLR1?
Yes, FOLR1 high or medium expression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 100 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify